Autolus Therapeutics plc (AUTL) stock
AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3020% below fair value
$1.09−0.05 (-4.39%)
Close on Nov 17, 2026Market cap $290.12MP/E –Yield –
Autolus Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Autolus Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $112.63M, down 10.1% year over year. For fiscal 2025 it was $117.69M, down 15.0% from the year before. The highest annual figure on record is $138.44M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $117.69M | -15.0% |
| FY2024 | Dec 31, 2024 | $138.44M | +6.1% |
| FY2023 | Dec 31, 2023 | $130.48M | +11.2% |
| FY2022 | Dec 31, 2022 | $117.35M | +5.9% |
| FY2021 | Dec 31, 2021 | $110.84M | -17.8% |
| FY2020 | Dec 31, 2020 | $134.89M | +273.1% |
| FY2018 | Sep 30, 2018 | $36.15M | +125.8% |
| FY2017 | Sep 30, 2017 | $16.01M | +53.4% |
| FY2016 | Sep 30, 2016 | $10.44M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $27.90M | +1.7% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $21.21M | -20.7% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $35.63M | +15.6% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $27.89M | -30.8% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $27.43M | -25.1% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $26.73M | -12.8% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $30.83M | -17.9% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $40.32M | +24.8% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $36.61M | +10.2% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $30.67M | +12.0% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $37.54M | +397.4% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $32.32M | +2.6% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $33.23M | +7.9% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $27.39M | -3.4% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $7.55M | -75.4% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $31.49M | -18.7% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $30.79M | -8.2% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $28.37M | -9.5% |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $30.73M | -1.8% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $38.73M | +283.6% |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | $33.55M | +278.5% |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | $31.33M | +463.0% |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | $31.29M | – |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $10.10M | – |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $8.86M | – |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $5.56M | – |
See a number that looks wrong?